Labcorp Holdings Inc. (LH) News
Follow Labcorp Holdings Inc. (LH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 77 public stories across 28 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Land and Houses Posts Quarterly Net Profit of 818.3 Million Baht
EQUITY | Nov 12, 2026, 03:45 PM UTC
M
Labcorp completes acquisition of Millennium Health
MNA | Nov 04, 2026, 01:39 PM UTC
M
Labcorp Reports Third-Quarter Revenue of $3.81 Billion, EPS of $3.22
Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% year over year, and net income of $262.8 million, up 0.7%. Diluted EPS rose 3.2% to $3.22; growth reflected organic gains and acquisitions, net of div
EQUITY | Oct 30, 2026, 08:21 PM UTC
M
Company Reports FY2026 Third-Quarter Profit of 8.393亿美元
Profit attributable to shareholders rose 17.91% year over year; basic earnings per share was 10.27美元.
EQUITY | Oct 29, 2026, 03:13 AM UTC
M
Labcorp and Chemed shares surge after third-quarter earnings
Labcorp shares were up around 10.4% and Chemed shares gained 9% on Wednesday, reaching over 52-week highs, according to the report. It attributes the moves to stronger-than-expected third-quarter earnings and bullish Wal
EQUITY | Oct 28, 2026, 05:57 PM UTC
M
Labcorp shares rise 10% as FY26 revenue outlook tops estimates
Labcorp sees FY26 revenue above estimates, and its shares are up 10%.
EARNINGS | Oct 28, 2026, 05:14 PM UTC
M
Labcorp Raises FY Adjusted Earnings and Revenue Guidance; Shares Gain 10%
Labcorp raised its full-year adjusted earnings and revenue guidance. Shares rose 10% to $365.02 in midday Wednesday trading; the stock is up 46% year to date.
EARNINGS | Oct 28, 2026, 04:52 PM UTC
M
Labcorp Raises 2026 Guidance as Q3 Earnings and Revenue Rise
Labcorp reported higher Q3 adjusted earnings and revenue and raised its 2026 guidance.
EQUITY | Oct 28, 2026, 11:38 AM UTC
M
Labcorp reports Q3 profit of $262.8 million
Labcorp’s third-quarter profit was $262.8 million, or $3.22 per share, versus $261.1 million, or $3.12 per share, a year earlier.
EQUITY | Oct 28, 2026, 11:09 AM UTC
M
Labcorp Holdings Reports Third-Quarter Revenue of $3.81 Billion
EQUITY | Oct 28, 2026, 11:07 AM UTC
M
Labcorp Expects 2026 Revenue of $14.78B–$14.89B
Labcorp expects 2026 revenue of $14.78 billion to $14.89 billion, versus a FactSet estimate of $14.75 billion.
EARNINGS | Oct 28, 2026, 10:56 AM UTC
M
Labcorp Sees FY Adjusted EPS of $18.30-$18.70
EARNINGS | Oct 28, 2026, 10:55 AM UTC
L
Labcorp reports third-quarter adjusted EPS of $4.78
EARNINGS | Oct 28, 2026, 10:52 AM UTC
M
Labcorp Adjusted EPS Rises 15% in Q3 2026
Labcorp reported adjusted earnings per share up 15% for the third quarter of 2026.
EARNINGS | Oct 28, 2026, 10:52 AM UTC
M
Labcorp eleva 15% su BPA ajustado del tercer trimestre de 2026 a 4,78 dólares
EARNINGS | Oct 28, 2026, 10:52 AM UTC
L
Labcorp had seen 2026 revenue of $14.71B–$14.83B
EARNINGS | Oct 28, 2026, 10:52 AM UTC
M
Labcorp Issues Full-Year Revenue Growth Outlook
EQUITY | Oct 28, 2026, 10:51 AM UTC
M
Labcorp Q3 Revenue Reaches USD 3,810 Million
Labcorp reported Q3 revenue of USD 3,810 million, compared with the IBES estimate of USD 3,759 million.
EQUITY | Oct 28, 2026, 10:51 AM UTC
M
Labcorp forecasts FY adjusted EPS outlook
Labcorp's fiscal-year adjusted EPS outlook is above and below the supplied IBES estimate of USD 18.4.
EARNINGS | Oct 28, 2026, 10:51 AM UTC
M
Labcorp Reports Third-Quarter Results, Raises 2026 Guidance
Labcorp reported 2026 third-quarter results and raised its full-year 2026 guidance.
EQUITY | Oct 28, 2026, 10:50 AM UTC
M
Labcorp Reports Third-Quarter Net Income of $262.8 Million
EARNINGS | Oct 28, 2026, 10:50 AM UTC
M
Labcorp Q3'26 earnings preview provides estimates
Labcorp is scheduled to report Q3'26 results on October 28 before the market opens. Revenue and EPS estimates were provided.
EQUITY | Oct 27, 2026, 11:01 AM UTC
M
Labcorp Q3'26 Earnings Preview
Labcorp is scheduled to report Q3'26 results on October 28 before the market opens.
EQUITY | Oct 21, 2026, 11:00 AM UTC
M
Myriad Genetics Agrees to Sell Prenatal Testing Business to Labcorp
Myriad Genetics agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash plus inventory value. Myriad shares rose 22.2% in premarket trading.
MNA | Oct 20, 2026, 02:21 PM UTC
M
Labcorp to Buy Myriad Genetics Prenatal Testing Business for $210 Million
Myriad Genetics agreed to sell its prenatal health testing business to Labcorp for $210 million in cash plus the value of inventory. The business includes Prequel, Foresight, SneakPeek and FirstGene.
MNA | Oct 20, 2026, 01:02 PM UTC
M
Myriad Genetics to Sell Prenatal Testing Business to Labcorp for $210M
Myriad Genetics will receive $210 million in cash plus the value of inventory at closing.
MNA | Oct 20, 2026, 12:43 PM UTC
M
Myriad Genetics to Sell Prenatal Testing Business to Labcorp
Myriad Genetics and Labcorp announced a definitive agreement for Myriad to sell its prenatal health testing business to Labcorp.
MNA | Oct 20, 2026, 12:42 PM UTC
L
Labcorp Expects Transaction to Add to Adjusted Earnings in Year One
Labcorp expects the transaction to be slightly accretive to adjusted earnings in year one and reach average diagnostics segment margins by the end of year two, once fully integrated.
MNA | Oct 20, 2026, 12:35 PM UTC
M
Labcorp to Buy Opko Health Unit Assets for Up to $872 Million
Labcorp said it will pay $722 million in cash, with up to $150 million more tied to revenue from a prostate cancer test.
MNA | Oct 15, 2026, 12:14 PM UTC
M
Labcorp Agrees to Acquire BioReference Health Assets for $722 Million
Labcorp agreed to acquire select assets of BioReference Health, a subsidiary of OPKO Health, for $722 million in cash at closing.
EQUITY | Oct 15, 2026, 12:08 PM UTC
M
Labcorp Agrees to Acquire Select BioReference Health Assets
Labcorp entered into an agreement with OPKO Health to acquire select assets of BioReference Health.
EQUITY | Oct 15, 2026, 11:34 AM UTC
M
Labcorp Transaction Purchase Price Is $722 Million in Cash
MNA | Oct 15, 2026, 11:34 AM UTC
M
Labcorp to announce Q3 2026 results on Oct. 28
Labcorp said it will report third-quarter 2026 financial results on October 28, 2026.
EQUITY | Sep 30, 2026, 12:30 PM UTC
L
Weekly Recap: Medicare lab payment cuts and Labcorp growth targets
Labcorp Holdings Inc. (NYSE:LH) plunged after CMS proposed cutting Medicare lab payments to private-sector levels, with shares down intraday and 5.9% premarket to $254.42; the company warned the steep 2027—2029 cuts coul
EARNINGS | Sep 28, 2026, 11:06 AM UTC
H
Labcorp Reaffirms 2026—2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029
On September 21, 2026, the Centers for Medicare & Medicaid Services ("CMS") released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the Protecting Access to Medic
LIVE | Sep 22, 2026, 08:46 PM UTC
M
Diagnostic-testing stocks drop after proposed Medicare lab payment cuts
Labcorp and Quest Diagnostics shares fell in premarket after CMS proposed cuts to Medicare payment rates for laboratory services.
EQUITY | Sep 22, 2026, 01:10 PM UTC
H
LH: Reaffirmed strong growth outlook, driven by specialty testing, tech, and strategic acquisitions
Long-term guidance through 2026 was reaffirmed, with strong revenue and EPS growth targets, margin expansion, and robust free cash flow. Specialty testing, technology investments, and acquisitions are key growth drivers,
EARNINGS | Sep 15, 2026, 05:10 PM UTC
H
LH: Reaffirmed 2026 guidance highlights specialty testing, AI, and acquisitions as key growth drivers
Long-term guidance through 2026 was reaffirmed, with strong revenue and EPS growth targets, margin expansion, and robust free cash flow. Specialty testing, technology investments, and acquisitions are key growth drivers,
EARNINGS | Sep 15, 2026, 04:37 PM UTC
M
Labcorp outlines 2026 guidance and long-term outlook
Labcorp reaffirmed 2026 guidance and gave a 2026-2029 outlook targeting 5%-8% revenue CAGR and 8.5%-11.5% adjusted EPS CAGR. It also cited $18.10-$18.55 in 2026 adjusted EPS guidance.
EARNINGS | Sep 10, 2026, 08:54 PM UTC
M
Labcorp presents 2026 guidance and 2029 growth targets
Labcorp Holdings reaffirmed full-year 2026 adjusted EPS guidance of $18.10 to $18.55 and sales guidance of $14.710 billion to $14.827 billion at its 2026 Investor Day. The company also outlined 2029 targets for 5% to 8%
EARNINGS | Sep 10, 2026, 05:40 PM UTC
H
Labcorp backs guidance: EPS $18.10–$18.55, revenue $14.71B+
Labcorp backed its year guidance and projected further gains ahead as it expects to outperform the laboratory services market. The company said it continues to expect adjusted earnings per share of $18.10 to $18.55 and r
EARNINGS | Sep 10, 2026, 01:01 PM UTC
H
Labcorp provides outlook through 2029 and reaffirms 2026 guidance
Labcorp issued its outlook through 2029. The company expects compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by end-2029, and compound annual adjusted EPS growth
EARNINGS | Sep 10, 2026, 11:32 AM UTC
H
Labcorp reaffirms outlook through 2029 with 5%-8% revenue CAGR
Labcorp reaffirms full-year 2026 guidance and provided a long-term outlook through 2029. It expects compound annual revenue growth of 5% to 8% and compound annual adjusted EPS growth of 8.5% to 11.5%.
EARNINGS | Sep 10, 2026, 11:16 AM UTC
H
Labcorp affirms FY2026 adj EPS guidance at $18.10-$18.55
Labcorp Holdings (LH) affirmed FY2026 adjusted EPS guidance of $18.10–$18.55 versus a $18.01 analyst estimate. It also affirmed FY2026 sales guidance of $14.710B–$14.827B versus a $14.707B estimate.
EARNINGS | Sep 10, 2026, 11:11 AM UTC
H
Labcorp sees 2026 free cash flow at $1.24B-$1.36B
EARNINGS | Sep 10, 2026, 11:08 AM UTC
L
Labcorp Holdings Backs 2026 View of Rev $14.71B-$14.83B >LH
Labcorp Holdings Backs 2026 View of Rev $14.71B-$14.83B >LH
EQUITY | Sep 10, 2026, 11:07 AM UTC
H
Labcorp Sees Adjusted Operating Margin Expansion of 75-150 Basis Points by End of 2029 >LH
Labcorp Sees Adjusted Operating Margin Expansion of 75-150 Basis Points by End of 2029 >LH
EARNINGS | Sep 10, 2026, 11:07 AM UTC
H
Labcorp Holdings Sees Compound Annual Revenue Growth of 5%-8% Through 2029 >LH
Labcorp Holdings Sees Compound Annual Revenue Growth of 5%-8% Through 2029 >LH
EARNINGS | Sep 10, 2026, 11:06 AM UTC
L
LH - Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
LH - Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
EQUITY | Sep 10, 2026, 11:01 AM UTC
H
Labcorp Holdings Reaffirms Full-Year 2026 Guidance >LH
Labcorp Holdings Reaffirms Full-Year 2026 Guidance >LH
EQUITY | Sep 10, 2026, 11:01 AM UTC
L
Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
BURLINGTON, N.C., Sept. 10, 2026 // -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m. ET, where the company will provide an in-dept
EQUITY | Sep 10, 2026, 11:01 AM UTC
H
Labcorp sees FY adjusted EPS range $18.10–$18.55
EARNINGS | Sep 10, 2026, 11:00 AM UTC
L
NYSE pre-market daily advisory issued for upcoming trading
NYSE issued a pre-market daily advisory direct from the NYSE Trading Floor, providing a daily update ahead of the trading session.
EQUITY | Sep 09, 2026, 12:55 PM UTC
M
Labcorp Holdings to acquire MLM Medical Labs
Labcorp Holdings (LH) announced it has acquired MLM Medical Labs, a central and specialty laboratory provider operating across the United States, Germany and South Africa. Financial terms were not disclosed.
MNA | Sep 08, 2026, 01:59 PM UTC
M
Labcorp to acquire MLM Medical Labs, expanding clinical trial labs
Labcorp will acquire MLM Medical Labs to expand its global central laboratory and biomarker capabilities for clinical trials.
EQUITY | Sep 08, 2026, 01:06 PM UTC
L
Labcorp to present executives at Morgan Stanley global healthcare conference Sept. 15
Labcorp said it will present executives at the Morgan Stanley Global Healthcare Conference on Sept. 15. A webcast will be available.
EQUITY | Aug 28, 2026, 12:44 PM UTC
L
Labcorp to speak at Morgan Stanley Global Healthcare Conference
Labcorp said it will speak at the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Aug 28, 2026, 12:30 PM UTC
L
Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Aug 28, 2026, 12:30 PM UTC
M
Labcorp to offer first FDA-cleared blood test for Alzheimer’s pathology
Labcorp says it will offer the first FDA-cleared blood test to detect Alzheimer’s disease pathology in both primary and specialty care settings.
REGULATION | Aug 24, 2026, 11:04 AM UTC
L
LabCorp plans nationwide availability of test in coming months
LabCorp says it plans nationwide availability of a test in coming months, without providing the test name, timing details, or catalyst.
EQUITY | Aug 24, 2026, 11:03 AM UTC